Merck-backed MilliporeSigma, a life sciences company, agreed to acquire Mirus Bio, a transfection reagents, electroporation solutions and related products company, from KKR-backed Gamma Biosciences, a life sciences tools platform, for $600m. “We have been driving innovation in nucleic acid delivery for two decades. MilliporeSigma’s broad portfolio, scale, and global reach, combined with our leading transfection reagents, will help take our business to even greater heights and allow us to serve more customers, and ultimately patients, worldwide,” Dale Gordon, Mirus Bio CEO.